Mansfield Bio-Incubator’s Post

✨ ✨ ✨ I'd like to kick off a new series highlighting some of the best and brightest across the Life Science space ✨ ✨ ✨   My first instalment of this kicks off with a company doing incredible work in the Drug Design space... 🥁 🥁   Exscientia   🔎 They utilise precision information derived from patient tissues alongside sophisticated AI technology to source optimised drug profiles for research. This integrated system has been the first to demonstrate improved clinical outcomes in oncology, and I believe that is just the beginning in their revolution.   📈 They currently have four targets at pre clinical, and phase 1-2, across Haematology, Oncology, and Inflammatory Diseases. With 40% of total clinical growth within Biotech/ Pharmaceuticals sitting within Oncology in 2023, Exscientia should be on your radar!   🗞 With the recent appointment of Marie-Louise Fjaellskog, and promotion of John Overington, I can't wait to see the continued success of this truly pioneer company. #Biotech #innovation #AI #DrugDesign

Our #STATSummit kicks off next week! You can still register here: https://trib.al/Hvd9idz. See details on our Day 2 agenda below ⬇️ 🗣️ Alnylam Pharmaceuticals turned Nobel-winning lab research into a new class of drugs. Now it's seeking to develop a drug in an area #biotech firms have long avoided: #cardiology. Adam Feuerstein will talk with the company's CEO Dr. Yvonne Greenstreet. 🗣️ Twice, Tony Coles has run a #biotech firm that was sold for a price approaching $10 billion. He’s also the co-chair of the Black Economic Alliance. Hear how he balances it all. 🗣️ Scientists see a radical transformation as single-cell sequencing technologies allow us to watch the inner workings of cells, right down to the level of individual molecules. Take a look with Anne Carpenter, Sarah Teichmann FMedSci FRS, and Kun Zhang. Broad Institute of MIT and Harvard SyzOnc Cambridge Stem Cell Institute Altos Labs 🗣️ In the wake of a personal tragedy, investor and musician D.A. Wallach discovered the alarming state of medical standards. He’ll share his vision for a future in which #medicine becomes a true science with Nicholas St. Fleur. 🗣️ Author Atul Gawande sits down with Sarah Owermohle to discuss his current chapter fighting for #globalhealth at USAID, and so much more. 🗣️ Few things are tougher than creating a new medicine. Jane Grogan, Jay Bradner, and Andy Plump share how they are taking on the toughest problems in biology with Elaine Chen. Biogen Amgen Takeda 🗣️ A new project from Bob Duggan and Dr. Maky Zanganeh has caught the interest of scientists, physicians, and investors. Hear more about the experimental treatment for #lungcancer from Summit Therapeutics, Inc. 🗣️ The development of new treatments relies on two types of data: information about basic #biology, used to invent experimental medicines, and new ways to understand whether those potential treatments are safe and effective. Amy Abernethy will share her thoughts. Highlander Health 🗣️ A new generation of #raredisease parents are taking science into their own hands, developing drugs for their children even though traditional industry isn't interested. Allyson Berent, Michelle Werner, and Terry Pirovolakis tell their stories. Foundation for Angelman Syndrome Therapeutics Elpida Therapeutics Alltrna Flagship Pioneering We hope to see you in Boston!

🏗 Arena BioWorks Launches New Biomedical Research Institute in Cambridge In recent developments within the biomedical sector, Arena BioWorks has inaugurated its research institute in Cambridge, MA. The institute, led by Harvard scientist Stuart Schreiber, aims to contribute to the understanding and treatment of human diseases.   Key Highlights:  1️⃣ Leadership: Arena BioWorks is led by a team of scientists including Stuart Schreiber. 2️⃣ Funding Model: The institute operates on a private funding model, aiming to facilitate research and development in therapeutics. 3️⃣ Research Focus: Areas of focus include oncology, brain health, and aging, among others. 4️⃣ Industry Implications: This new institute is expected to add to the research efforts in the biomedical field, with potential implications for future therapeutic developments.   For more detailed analysis and updates on Arena BioWorks and its impact on the healthcare sector, follow our coverage. #BiomedicalResearch #ArenaBioWorks #HealthcareSector #ResearchAndDevelopment

This is great news! At ZAKA VC we’ve just unveiled yet another investment that promises to speed-up the progress in target medicine, combating cancer, cardiometabolic diseases, and neurodegenerative disorders. Lime Therapeutics does it with their unique ground-breaking technology LipidSense™ which allows for the rapid measurement of lipid flow in cells at an unprecedented speed – over 20,000 times faster than the current standard. This not only accelerates the pace of lipidomic research but also enables the identification of potential new drugs that can alter lipid biology, thus opening doors to novel therapeutic avenues. Moreover, LipidSense™ is rapidly deployable and scalable. Founded by a visionary trio – Shardule Shah, PhD, MBA, Prakrit Jena, and Daniel Heller – Lime Therapeutics is set to redefine the landscape of human health by unlocking a new class of lipid-targeting medicines - an area that has long been overlooked despite its critical importance in human health. Co-founders also share the commitment to bridge the gap between scientific discovery and tangible patient outcomes. This approach has not only attracted top talent, but has also secured significant partnerships and funding, including collaborations with renowned institutions and industry giants like Novo Nordisk. So, we at ZAKA VC are more than proud to support their mission, to help put them into the limelight. #newinvestment #biotech #limetherapeutics

🌟 Biotech Insight Alert! 🌟 Take a look at an overview of Cancer's latest investment trends from the CipherBio dashboard through February 22! ✨ Key Takeaways: - A whopping $3.6B has been invested across 16 dynamic companies, showcasing the robust health of the biotech sector. - Biotech leads the charge with the highest funding, followed by a strong showing in diagnostics and medical devices. - Our data highlights notable activity with the most active investors and top indications leading the way in oncology and infectious diseases. 🔍 Dive into the Details: - The market is buzzing with top scientific approaches like Artificial Intelligence (AI) in drug discovery and innovative treatments in immuno-oncology. - Strategic investments significantly advance solid tumors, sepsis, and ovarian cancer research. - We're seeing a global reach with key investments spanning from Cambridge to Shanghai. 🚀 Top Deals & Indications: - Keep an eye on our top deals, including significant series fundings and acquisitions. - Clinical stages by indication reveal a concentrated investment in Phase 1 and 2 trials, promising a future of groundbreaking therapies. This visual snapshot is just the beginning. For those who are as passionate about the future of healthcare as we are, let's connect and discuss how these developments will pave the way for innovative solutions and patient care. Swipe through and let's start a dialogue on these exciting trends! #HealthcareInvestment #BiotechBoom #InnovationTrends #CipherBio #InvestmentInsights #ClinicalDevelopment #GlobalHealthcare #VentureCapital #Biotechnology #LifeSciences #Cancer

🗣 Exciting discussion with Dr. Sharon (Sharon Benzeno) from Adaptive Biotechnologies Corp. on the future of biotechnology at the #FierceBiotechSummit 2023. Generative biology is revolutionizing scientific progress by combining AI and ML with innovations in biology. From identifying T-cell signatures to breakthroughs in drug discovery, the potential for improving treatments for cancer, autoimmune disorders, and neurodegenerative diseases is limitless. The key? Scale, speed, and cost efficiency. The future of drug discovery looks bright! 🔗Full Interview: https://lnkd.in/gHx5Nm3T 💡 Join us at the Fierce Biotech Summit 2024 on September 30 - October 1, 2024 in Boston, MA! Click the link below to be a part of our mailing list and be the first to know when registration will open: https://lnkd.in/ewhc9xFk ❗ Stay updated on all our events by following Fierce Life Sciences Events #WeAreFierce #FierceBiotechSummit #FierceBiotech #Biotech #Science #Innovation #BiotechInnovation #DrugDiscovery #GenerativeBiology #HealthTech #AIinHealthcare #MachineLearning

Mestag harnesses new insights into fibroblast-immune interactions to develop impactful treatments for patients. We are progressing a pipeline of sophisticated first-in-class antibodies designed to improve the lives of patients with cancer and inflammatory disease. Together with our collaboration partner Janssen Biotech, Inc. we are also identifying novel targets for future therapies. Our founding investigators comprise global experts in inflammatory disease, cancer, computational biology and fibroblast biology from the University of Oxford, Brigham & Women’s Hospital, Harvard Medical School and Cold Spring Harbor Laboratory. We are supported by leading life science investors SV Health Investors, Johnson & Johnson Innovation – JJDC, Inc., Forbion, GV (formerly Google Ventures) and Northpond Ventures. Mestag is headquartered in Cambridge, UK, and in 2021 was recognized on the Fierce 15 list of innovative biotechnology companies. Meet Mestag Therapeutics @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW

Happy #InternationalWomensDay to the women leading the Intelligent Bioscience revolution! As a women-founded and women-led firm, we are especially proud to celebrate the female founders who lead the Breakout Ventures portfolio companies: (𝘍𝘪𝘳𝘴𝘵 𝘳𝘰𝘸) Etosha Cave, PhD is the CSO, and Kendra Kuhl, PhD is the CTO at Twelve, a DeepTech company on a mission to build a fossil-free future through the science of carbon transformation. Ivana Muncie-Vasic, PhD is the CEO at Vitra Labs, a biotech startup developing cell-based therapies that to make IVF safer and more accessible to all patients struggling with infertility. Jennifer Power is the CEO of TFC Therapeutics, a biotech startup blending early-stage research with innovative platform design to develop next-generation treatments to eliminate the most resilient cancers. (𝘚𝘦𝘤𝘰𝘯𝘥 𝘳𝘰𝘸)  Jennifer Schneider, MD, is the President of Surf Bio, a preclinical biopharmaceutical company leveraging surfactants to develop therapeutic solutions for diabetes, oncology, infectious diseases, and gene therapy. Juliana L. Hilliard is the CSO of Parallel Bio, which is building a platform that replicates the human immune system in a dish across populations to discover cures at a pace never seen before. Wendye Robbins, MD is the CEO of Incendia Therapeutics, a precision oncology biotech company dedicated to reprogramming the tumor microenvironment. Women's leadership and insights are crucial to shaping the world's bio-based transformation. Integrating diverse perspectives fuels our mission of reaching a healthier, more sustainable future. 𝐂𝐡𝐞𝐞𝐫𝐬 𝐭𝐨 𝐛𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐛𝐚𝐫𝐫𝐢𝐞𝐫𝐬, 𝐟𝐨𝐫𝐠𝐢𝐧𝐠 𝐧𝐞𝐰 𝐩𝐚𝐭𝐡𝐬, 𝐚𝐧𝐝 𝐛𝐮𝐢𝐥𝐝𝐢𝐧𝐠 𝐚 𝐥𝐞𝐠𝐚𝐜𝐲 𝐭𝐡𝐚𝐭 𝐢𝐧𝐬𝐩𝐢𝐫𝐞𝐬 𝐟𝐮𝐭𝐮𝐫𝐞 𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧𝐬 𝐨𝐟 𝐭𝐫𝐚𝐢𝐥𝐛𝐥𝐚𝐳𝐞𝐫𝐬! #IWD2024 #InternationalWomensDay2024 #WomenInScience #WomenFounders #WomenInLeadership #WomenInBiotech

Great news: 👏Our Deep Tech portfolio company eleva recently shared promising preclinical data in the 'Frontiers in Immunology' journal. eleva developed a special treatment called CPV-104 to help people with complement-related issues. CPV-104 targets problems in the body's complement system, which can cause diseases like 🔸C3 Glomerulopathy (C3G), 🔸aHUS, 🔸and dry AMD. The advantage of CPV-104 is that it fixes these issues without compromising the body's ability to fight infections. Tests with CPV-104 showed that can restore kidney health and reduce harmful deposits. eleva plans to conduct clinical trials at the beginning of 2025. Andreas Schaaf, Chief Scientific Officer at eleva, stated: “CPV-104 has the potential to provide a therapeutic option that is clearly differentiated from the standard-of-care by leaving the immune system’s ability to fight infections intact.” We are hopeful for for further positive results and are delighted to have a company in our portfolio that is committed to people's health. You can find more about eleva on their website linked in our comments ⤵️. We will also link the research article. Have fun reading☺️🔖. #startups #vc #eleva #management #entrepreneurship #innovation 

𝗘𝗻 𝗖𝗮𝗿𝘁𝗮 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝘀𝗲𝗰𝘂𝗿𝗲𝘀 €𝟭.𝟱𝗠 𝘁𝗼 𝗮𝗱𝘃𝗮𝗻𝗰𝗲 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗸𝗶𝘁 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺 𝗳𝗼𝗿 𝗲𝗮𝗿𝗹𝘆 #𝗟𝘆𝗺𝗲 #𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻: En Carta Diagnostics, a deeptech start-up developing rapid Point-of-Care (POC) molecular diagnostics kits, announces €1.5M ($1.63M) in pre-seed funding. This investment will enable En Carta to make a substantial leap forward in achieving preclinical data on a prototype diagnostic kit for its flagship indication, the debilitating Lyme disease, while ensuring its ability to scale industrially. CentraleSupélec Venture led the round with participation from a handful of high-profile business angels. Additional funding may be forthcoming to finance other diagnostic platform derivatives. 𝗚𝗿𝗼𝘂𝗻𝗱𝗯𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗽𝗮𝘁𝗲𝗻𝘁𝗲𝗱 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗸𝗶𝘁 𝗽𝗼𝗶𝘀𝗲𝗱 𝘁𝗼 𝗽𝗿𝗼𝘃𝗶𝗱𝗲 𝗴𝗮𝗺𝗲-𝗰𝗵𝗮𝗻𝗴𝗶𝗻𝗴 𝗮𝘂𝘁𝗼𝗻𝗼𝗺𝗼𝘂𝘀 𝗟𝘆𝗺𝗲 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝗶𝗻 𝗺𝗶𝗻𝘂𝘁𝗲𝘀: https://lnkd.in/ekwEdA6M Margot Karlikow, PhD, Guillaume Horréard, Cédric Curtil, Carol Leslie, Juliette Schmitt